Professionals 205 Users Online

Hematology Analyzers Market

Increasing Demand for Point-of-Care Testing Drives Hematology Analyzers Market

Hematology Analyzers Market by Product (3-Part, 5-Part), 5-part hematology analyzers held a market share of around 72.8% in the global market.

Hematology Analyzers Market Outlook (2023 to 2033)

The global revenue from the Hematology Analyzers Market was around US$ 1.31 Billion in 2022, with the global market expected to grow at a CAGR of 4.8% to reach a valuation of about US$ 2.20 Billion by the end of 2033.

Attributes Key Insights

Market Size (2023)

US$ 1.37 Billion

Projected Market Value (2033)

US$ 2.20 Billion

Global Market Growth Rate (2023 to 2033)

4.8% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, 5-part hematology analyzers held a market share of around 72.8% in the global market, in 2022. Overall, hematology analyzers market sales account for around 38.0% of revenue share in the Global Haemotology Diagnostics market, which was valued at around US$ 3.5 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 3.9% in the last 7 years from 2015 to 2022.

More information can be provided by advanced hematology analyzers, both quantitatively and qualitatively, such as suspicious flags (used to detect errors). It is more effective to have access to real-time graphical data since it gives information on aberrant cell populations and illness patterns. The global population is using hematological analyzers on broader scale as a result of this technical improvement.

The global market is anticipated to grow at a rapid rate throughout the forecast period as a result of the continuously expanding research and development efforts in a number of fields, including stem cell research, gene therapies, targeted therapies, blood disorders, thalassemia, and omics. Owing to this trend the market will continue to thrive over the forecast period as well. The growth is also attributed to a variety of factors, including increased public awareness and the presence of numerous diagnostic facilities.

Leading manufacturers are concentrating on innovation-based approaches, utilising opportunities for scientific development with advancements in the field of diagnostics and testing. The introduction of new technological developments and the development of cellular analysis software has improved the effectiveness of analysis and data management, which has resulted in greater sales.

The market is expected to be driven by increasing chronic disease awareness around the world over the forecast period. Chronic diseases are the primary cause of death and illnesses across the globe. People from all socioeconomic classes are being affected by the rising prevalence of chronic diseases on a global scale. In the future, more hematology analyzers will be utilized by people for early diagnosis and treatment of such diseases in order to slow down the progression rate of such diseases.

The global market is likely to show high growth over the coming years at a CAGR of 4.8% and reach a global market size of US$ 2.20 Billion by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Increasing Cases of Blood Disorders in Infants and Constant Product Innovation to Offer Lucrative Opportunities for the Market

Over the past years, blood analysis has become more popular for the early diagnosis of several chronic diseases, which were previously only achievable through tissue biopsy studies. Hematology analyzers market growth is significantly influenced by improvements in blood indicators for diseases.

  • Anemia, blood cancer, cerebrovascular diseases, and blood infections are among the blood disorders that affect thousands of people annually in all age groups. In 2022, Department of Health and Aged Care reported that there were more than 330,000 affected infants (83% of those babies had sickle cell disorders), among the expecting mothers, more than 7-8% of pregnant women carried hemoglobin disorders, and over 1-2% of couples worldwide were at risk of it.

More than 1,125,000 men globally had an inherited bleeding problem, and over 418,000 of those had a severe form of the most undiagnosed disease, according to a World Federation of Hemophilia, July 2022. The safest way to protect a patient with blood disorders and maintain the quality of life is by early diagnosis and treatment. Therefore, the market is projected to be driven in the future by the rising burden of blood disorders.

Furthermore, it is predicted that the market will also rise in the future due to the increasing adoption rate of automated hematology analyzers and the integration of AI-based hematology analyzers along with growing preferences towards high sensitivity hematology testing.

Furthermore, automation has initiated more opportunities in the market by encouraging the development of new instruments like automated erythrocyte sedimentation rate (ESR) systems, integrated slide-makers, HbA1c systems, tube sorters, and electronic morphology systems that are connected to middleware. This continuous product innovation and their commercialization will create high demands for haematology analyzers throughout the forecast period.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

High Cost of the Products and Stringent Regulatory Scenario to Impede the Market Growth

Modern products available on the market are not accepted or preferred in underdeveloped countries. Another significant factor is product recalls and concerns about the product's efficacy and safety, this factor is anticipated to limit the market's growth. Lack of preference, which slows this device's adoption in developing nations, is a factor that restricts market growth.

Market growth is anticipated to be restricted over the anticipated period by competitiveness between current players and the high cost of haematology analyzers. Additionally, it is anticipated that the market would not expand during the projected period due to the time-consuming and stringent regulatory standards for hematology analyzers.

  • For example, portable hematology analyzers from Wuhan Darppon Medical Technology Co, Ltd. costs between US$ 4800 to US$5500. Due to their exorbitant prices, these items have limited adoption rates and are unable to compete and lowly preferred by the people in underserved regions and emerging markets.
Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Rising Prevalence of Blood Disorders and Increased Adoption Rates of the Hematology Analyzers”

The United States accounted for around 90.3% market share in the North America market in 2022.

Due to the rising prevalence of blood disorders in the country, the U.S. is predicted to account for the greatest portion of the market in terms of revenue. For instance, the WHO estimates that more than three million U.S. citizens, mostly young women, suffer from anemia, a common blood disorder. Future market expansion is also anticipated to be fueled by the increased acceptance of hematology analyzers by the diagnostic sector and the country's technological advancements in diagnostic instruments.

Will the U.K. Be a Lucrative Market for Hematology Analyzers?

“Presence of Major Players and Well Developed Research and Development Sectors”

The U.K. market held around 24.3% market share of the Europe market in 2022.

High emphasize on research and development activities in the analysing analyzers industry with constant product development and innovation coupled with presence of well-established players and high government expenditures will lead to market expansion in the U.K. over the forecast period.

  • Many players are considering 3D to be an evolving and innovative field. For instance, Mindray launched their SF cube technology in June 2019. This technology targets blood cells utilizing bi angular laser scattering signals and fluorescence signals, and it generates 3D scatter grams that reveal cellular information.

How is China Emerging as a Prominent Market?

“Increasing Utilization of Automated Hematology Instruments”

China held a market share of about 50.2% of the East Asia market in 2022.

The market is expected to grow due to the increased frequency of thalassemia in the general population, rising adoption rates of automated hematology instruments, and rising demand for high sensitivity point-of-care (POC) haematology testing.

  • According to a study that was published in the journal Hematology, Volume 27, 2022, 26.76% of people of reproductive age had thalassemia in south-western Chinese region.

Thus, the rising cases of blood disorders will create lucrative demands for the market and uplift the sales in the coming times.

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Better Efficacy in Providing Clinical Information”

The 5-part segment held around 72.8% share of the total market in 2022.

Throughout the forecast period, it is projected that the 5-part hematology analyzers segment would hold the dominant market share, owing to the fact that it is very affordable and offers information sufficient for the majority of clinical situations. In order to identify a variety of clinically significant conditions, such as autoimmune diseases and infections, 5-part analyzers offer crucial clinical information that is not possible with a 3-part analyzers.

Why Standalone Hematology Analyzers Are Largely Adopted within the Global Market?

“Better Handling of Large Quantity of Sample at Once with Efficient and Accurate Handling”

Standalone segment held around 54.3% share of the total market in 2022.

In comparison to point-of-care hematology analyzers, standalone hematology analyzers have a number of advantages, including the ability to handle a high quantity of samples efficiently and quickly, accuracy and precision in quantitative blood tests, the ability to run multiple tests on a single platform, a significant reduction in labor costs, and an unmatched ability to accurately determine red cell indices.

These machines are commonly used in healthcare environments like hospitals and diagnostic centres because of their effective features and these devices perform and handle multiple samples at once.

Which End User Predominantly Utilizes the Hematology Analyzers?

“Large Patient Pool Suffering from Blood Related Disorders Preferring in-Hospital Care”

Hospitals segment held around 42.7% share of the total market in 2022.

Chronic lead poisoning and sickle cell disease, as well as the rising prevalence of blood-related disorders like hereditary spherocytosis and cytochemistries on blood and bone marrow, all contribute to the dominance of hospitals segment in the market. Patients with such disorders choose to receive care and treatment in hospitals because of the presence of highly sophisticated equipment and technologies and care from medical professionals.

Competition Landscape

The majority of players are extremely committed to the development of novel products. In the last ten years, 6-part and 4-part hematology analyzers have been introduced, providing end users with more options to meet their needs. Along with this, a lot of attention is being paid to the creation of new features and automation of tools like 3D scatter maps and suspect mapping. Another important area of focus for market players in hematology analyzers is partnerships with distributors, which will improve product penetration globally.

Some key instances of development include:

  • In April 2022, he XQ-320, new 3-part differential automated hematology analyzer, was launched by Sysmex Europe. It is a reliable instrument with minimal requirements for bench space, sample volume, and maintenance in Europe.
  • In March 2022, the BC-700 Series, a ground-breaking line of hematology analyzers from Mindray was launched, contains both CBC and ESR tests for the complete blood count (CBC).

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the hematology analyzers market, which are available in the full report.

Hematology Analyzers Industry Report Scope

Attribute Details

Forecast Period

2023 to 2033

Historical Data Available for

2015 to 2022

Market Analysis

  • USD Million for Value
  • Units for Volume

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Modality
  • End user
  • Region

Key Companies Covered

  • Abbott Laboratories
  • Beckman Coulter Inc
  • Siemens AG
  • Boule Diagnostics AB.
  • Nihon Kohden Corporation
  • Mindray
  • HORIBA Ltd.
  • Diatron`
  • Cellavision
  • Edan Instrumnets, Inc
  • Biosystems SA
  • F. Hoffmann-La Roche Ltd.
  • Shenzhen Dymind Biotechnology Co. Ltd.
  • PixCell
  • Shenzhen Landwind Insdustry Co. Ltd.
  • Rayto Life and Analytical Sciences Co. Ltd
  • Shenzen Prokan Electronics Inc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Hematology Analyzers Industry Research


  • 3-Part
  • 5-Part
  • Others


  • Standalone
  • Point of Care

End User:

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Blood Banks


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Abbott Laboratories
  • Beckman Coulter Inc
  • Siemens AG
  • Boule Diagnostics AB.
  • Nihon Kohden Corporation
  • Mindray
  • HORIBA Ltd.
  • Diatron
  • Cellavision
  • Edan Instrumnets, Inc
  • Biosystems SA
  • F. Hoffmann-La Roche Ltd.
  • Shenzhen Dymind Biotechnology Co. Ltd.
  • PixCell
  • Shenzhen Landwind Insdustry Co. Ltd.
  • Rayto Life and Analytical Sciences Co. Ltd
  • Shenzen Prokan Electronics Inc.

- Frequently Asked Questions -

The global market is currently valued at around US$ 1.31 Billion in 2022.

Sales of the market are set to witness growth at a CAGR of 4.8% and be valued at around US$ 2.20 Billion by 2033.

Demand for the global market increased at a 3.9% CAGR from 2015 to 2022.

The U.S., China, Japan, the U.K., and France account for most demand within the market, currently holding around 65.9% market share.

The U.S. accounts for around 90.3% share of the North American market in 2022.

Latin America accounts for around 5.9% share of the global market in 2022.

The China market held a share of about 50.2% in the East Asia hematology analyzers market in 2022.

The U.K. hematology analyzers market is set to expand at 4.8% CAGR over the forecast period.

SYSMEX CORPORATION, Abbott Laboratories, Beckman Coulter Inc., Siemens AG are among some of the prominent players operating in the global market.

Rising prevalence of blood related disorders coupled with increasing adoption of automated hematology analyzers are few of the drivers that are propelling the global market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate